Nothing Special   »   [go: up one dir, main page]

DK2363488T3 - Postweaning multisystemisk wasting syndrom-virus fra grise - Google Patents

Postweaning multisystemisk wasting syndrom-virus fra grise Download PDF

Info

Publication number
DK2363488T3
DK2363488T3 DK10012196.1T DK10012196T DK2363488T3 DK 2363488 T3 DK2363488 T3 DK 2363488T3 DK 10012196 T DK10012196 T DK 10012196T DK 2363488 T3 DK2363488 T3 DK 2363488T3
Authority
DK
Denmark
Prior art keywords
pcvii
polypeptide
leu
arg
pro
Prior art date
Application number
DK10012196.1T
Other languages
English (en)
Inventor
Li Wang
Lorne A Babiuk
Andrew A Potter
Philipp Willson
Original Assignee
Merial Sas
Univ Belfast
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26749812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2363488(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Sas, Univ Belfast, Univ Saskatchewan filed Critical Merial Sas
Priority claimed from EP07008633.5A external-priority patent/EP1816200B1/en
Application granted granted Critical
Publication of DK2363488T3 publication Critical patent/DK2363488T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (13)

1. Isoleret immunogenisk porcin circovirus Type II (PCVII)-polypeptid omfattende: (a) MPSKKNGRSG PQPHKRWVFT LNNPSEDERK KIRELPISLF DYFIVGEEGN EEGRTPHLQG FANFVKKQTF NKVKWYLGAR CHIEKAKGTD QQNKEYCSKE GNLLIECGAP RSQGQRSDLS TAVSTLLESG ILVTVAKQHP VTFVKNFRGL AELLKVSGKM QKRDWKTNVH FIVGPPGCGK SKWAANFANP ETTYWKPPKN KWWDGYHGEK VVVIDDFYGW LPWDDLLRLC DRYPLTVKTK GGTVPFLARS ILITSNQTPL EWYSSTAVPA VEALYRRITS LVFWKNATKQ STEEGGQFVT LSPPCPEFPY EINY (ORF1); eller (b) polypeptid afledt fra ORF1 med mindst 98% identitet med den fulde længde af ORF1; eller (c) polypeptid afledt fra ORF1 med mindst 90% identitet med den fulde længde af ORF1; hvor polypeptidet ikke er MPSKKNGRSGPQPHKRWVFTLNNPSEDERKKIRDLPISLFDYFIVGEEGNEEGRTPHLQG FANFVKKQTFNKVKWYLGARCHIEKAKGTDQQNKEYCSKEGNLLMECGAPRSQGQRSDLS TAVSTLLESGSLVTVAEQHPVTFVRNFRGLAELLKVSGKMQKRDWKTNVHVIVGPPGCGK SKWAANFADPETTYWKPPRNKWWDGYHGEEVWIDDFYGWLPWDDLLRLCDRYPLTVETK GGTVPFLARSILITSNQTPLEWYSSTAVPAVEALYRRITSLVFWKNATEQSTEEGGQFVT LSPPCPEFPYEINY, eller MPSKKNGRSGPQPHKRWVFTLNNPSEDERKKIRELPISLFDYFIVGEEGXEEXRTPHLQG FANFVKKQTFNKVKWYLGARCHIEKAKGTDQQNKEYCSKEGNLLIECGAPRSQGQRSDLS TAVSTLLESGSLVTVAEQHPVTFVRNFRGLAELLKVSGKMQKRDWKTNVHVIVGPPGCGK SKWAANFADPETTYWKPPRNKWWDGYHGEEVWIDDFYGWLPWDDLLRLCDRYPLTVETK GGTVXXXARSILITSNQTPLEWYSSTAVPAVEALYRRITSLVFWKNATEQSTEEGGQXVT LSPPCPEFPYEINY; eller (d) fusionsprotein omfattende et hvilket som helst af (a) til (c).
2. Isoleret polypeptid ifølge krav 1, hvor polypeptidet er genereret ved kemisk syntese.
3. Isoleret polypeptid ifølge et hvilket som helst af kravene 1 til 2, hvor polypeptidet er genereret ved rekombinant produktion.
4. Isoleret polypeptid ifølge krav 3, hvor polypeptidet udtrykkes under anvendelse af baculovirus.
5. Rekombinant vektor omfattende et polynukleotid der koder for et immunogent PCVII-polypeptid som beskrevet i et hvilket som helst af kravene 1 til 4.
6. Rekombinant vektor ifølge krav 5, hvor den rekombinante vektor omfatter et polynukleotid der koder for det immunogene polypeptid MPSKKNGRSG PQPHKRWVFT LNNPSEDERK KIRELPISLF DYFIVGEEGN EEGRTPHLQG FANFVKKQTF NKVKWYLGAR CHIEKAKGTD QQNKEYCSKE GNLLIECGAP RSQGQRSDLS TAVSTLLESG ILVTVAKQHP VTFVKNFRGL AELLKVSGKM QKRDWKTNVH FIVGPPGCGK SKWAANFANP ETTYWKPPKN KWWDGYHGEK VVVIDDFYGW LPWDDLLRLC DRYPLTVKTK GGTVPFLARS ILITSNQTPL EWYSSTAVPA VEALYRRITS LVFWKNATKQ STEEGGQFVT LSPPCPEFPY EINY (ORF1).
7. Rekombinant værtscelle transformeret med vektoren ifølge krav 5 eller 6.
8. Rekombinant værtscelle ifølge krav 7, hvor den rekombinante værtscelle er en pattedyrcelle.
9. Rekombinant værtscelle ifølge krav 7, hvor den rekombinante værtscelle er en bakteriecelle.
10. Rekombinant værtscelle ifølge krav 7, hvor den rekombinante værtscelle er en gærcelle.
11. Rekombinant værtscelle ifølge krav 7, hvor den rekombinante værtscelle er en insektcelle.
12. Sammensætning omfattende et immunogent PCVII-polypeptid og en farmaceutisk eller veterinært acceptabel vehikel; hvor det immunogene PCVII-polypeptid omfatter: (a) MPSKKNGRSG PQPHKRWVFT LNNPSEDERK KIRELPISLF DYFIVGEEGN EEGRTPHLQG FANFVKKQTF NKVKWYLGAR CHIEKAKGTD QQNKEYCSKE GNLLIECGAP RSQGQRSDLS TAVSTLLESG ILVTVAKQHP VTFVKNFRGL AELLKVSGKM QKRDWKTNVH FIVGPPGCGK SKWAANFANP ETTYWKPPKN KWWDGYHGEK VVVIDDFYGW LPWDDLLRLC DRYPLTVKTK GGTVPFLARS ILITSNQTPL EWYSSTAVPA VEALYRRITS LVFWKNATKQ STEEGGQFVT LSPPCPEFPY EINY (ORF1); eller (b) polypeptid afledt fra ORF1 med mindst 98% identitet med den fulde længde af ORF1; eller (c) polypeptid afledt fra ORF1 med mindst 90% identitet med den fulde længde af ORF1; hvor polypeptidet ikke er MPSKKNGRSGPQPHKRWVFTLNNPSEDERKKIRDLPISLFDYFIVGEEGNEEGRTPHLQG FANFVKKQTFNKVKWYLGARCHIEKAKGTDQQNKEYCSKEGNLLMECGAPRSQGQRSDLS TAVSTLLESGSLVTVAEQHPVTFVRNFRGLAELLKVSGKMQKRDWKTNVHVIVGPPGCGK SKWAANFADPETTYWKPPRNKWWDGYHGEEVWIDDFYGWLPWDDLLRLCDRYPLTVETK GGTVPFLARSILITSNQTPLEWYSSTAVPAVEALYRRITSLVFWKNATEQSTEEGGQFVT LSPPCPEFPYEINY, eller MPSKKNGRSGPQPHKRWVFTLNNPSEDERKKIRELPISLFDYFIVGEEGXEEXRTPHLQG FANFVKKQTFNKVKWYLGARCHIEKAKGTDQQNKEYCSKEGNLLIECGAPRSQGQRSDLS TAVSTLLESGSLVTVAEQHPVTFVRNFRGLAELLKVSGKMQKRDWKTNVHVIVGPPGCGK SKWAANFADPETTYWKPPRNKWWDGYHGEEWVIDDFYGWLPWDDLLRLCDRYPLTVETK GGTVXXXARSILITSNQTPLEWYSSTAVPAVEALYRRITSLVFWKNATEQSTEEGGQXVT LSPPCPEFPYEINY? eller (d) fusionsprotein omfattende et hvilket som helst af (a) til (c).
13. Sammensætningen ifølge krav 12, yderligere omfattende en adjuvans.
DK10012196.1T 1997-12-11 1998-12-11 Postweaning multisystemisk wasting syndrom-virus fra grise DK2363488T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6923397P 1997-12-11 1997-12-11
US6975097P 1997-12-16 1997-12-16
EP07008633.5A EP1816200B1 (en) 1997-12-11 1998-12-11 Postweaning multisystemic wasting syndrome virus for pigs

Publications (1)

Publication Number Publication Date
DK2363488T3 true DK2363488T3 (da) 2014-11-24

Family

ID=26749812

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10012196.1T DK2363488T3 (da) 1997-12-11 1998-12-11 Postweaning multisystemisk wasting syndrom-virus fra grise
DK98959682T DK1037909T3 (da) 1997-12-11 1998-12-11 Postweaning multisystemisk wasting-syndromvirus (PMWS) fra svin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98959682T DK1037909T3 (da) 1997-12-11 1998-12-11 Postweaning multisystemisk wasting-syndromvirus (PMWS) fra svin

Country Status (19)

Country Link
US (3) US20020106639A1 (da)
EP (2) EP2363488B1 (da)
JP (5) JP3795751B2 (da)
KR (3) KR20060088908A (da)
CN (1) CN1309708A (da)
AT (1) ATE364624T1 (da)
AU (1) AU764379B2 (da)
BR (1) BR9813485A (da)
CA (1) CA2313806A1 (da)
CY (1) CY1107720T1 (da)
DE (2) DE69837934T2 (da)
DK (2) DK2363488T3 (da)
ES (2) ES2526760T3 (da)
HK (1) HK1102829A1 (da)
ID (1) ID28224A (da)
NZ (1) NZ505008A (da)
PT (2) PT1037909E (da)
RU (1) RU2000118777A (da)
WO (1) WO1999029717A2 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US7192594B2 (en) 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
CA2313806A1 (en) 1997-12-11 1999-06-17 University Of Saskatchewan Postweaning multisystemic wasting syndrome virus from pigs
EP1816200B1 (en) 1997-12-11 2016-03-09 Merial Postweaning multisystemic wasting syndrome virus for pigs
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
MXPA02012352A (es) * 2000-06-15 2004-09-06 Purdue Research Foundation Vacuna para temblores congenitos en cerdos.
US7276353B2 (en) * 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US8119337B2 (en) 2004-09-09 2012-02-21 Jens-Peter Gregersen Decreasing potential iatrogenic risks associated with influenza vaccines
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
SI1833992T1 (sl) 2004-12-30 2015-06-30 Boehringer Ingelheim Vetmedica, Inc. PCV2 imunogeni sestavki in postopki proizvodnje takšnih sestavkov
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
TW200643171A (en) * 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
EP3766518A1 (en) 2005-12-29 2021-01-20 Boehringer Ingelheim Animal Health USA Inc. Pcv2 immunogenic composition for lessening clinical symptoms in pigs
MX365868B (es) 2005-12-29 2019-06-18 Boehringer Ingelheim Vetmedica Inc Composiciones inmunogenicas de pcv2 multivalentes y metodos de producir composiciones de este tipo.
WO2008027558A2 (en) 2006-08-31 2008-03-06 Codon Devices, Inc. Iterative nucleic acid assembly using activation of vector-encoded traits
EP2859900A1 (en) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
UA103298C2 (ru) 2006-12-15 2013-10-10 Берингер Ингельхайм Ветмедика, Инк. Способ лечения молодых свиней с помощью антигена pcv2
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CN101294223B (zh) * 2007-05-08 2011-04-06 深圳太太基因工程有限公司 一种用于检测ⅱ型猪圆环病毒核苷酸片段的引物和探针序列
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
EP2231182A4 (en) * 2007-12-31 2012-08-22 Boehringer Ingelheim Vetmed PCV2-ORF2-VIRUSELY PARTICLES WITH FREMDAMINO-ACID INSERTION
JP5613061B2 (ja) 2008-01-23 2014-10-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
KR100983873B1 (ko) * 2008-07-04 2010-10-01 대한민국 돼지 써코바이러스 타입 1 및 2의 감별진단을 위한미니어레이법
US8703468B2 (en) 2008-11-28 2014-04-22 Ceva Sante Animale Porcine circovirus type 2B isolate and uses thereof
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
WO2011056872A2 (en) 2009-11-03 2011-05-12 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
ES2574055T3 (es) * 2009-11-25 2016-06-14 Gen9, Inc. Métodos y aparatos para la reducción de errores en el ADN basada en un chip
US9216414B2 (en) 2009-11-25 2015-12-22 Gen9, Inc. Microfluidic devices and methods for gene synthesis
US9217144B2 (en) 2010-01-07 2015-12-22 Gen9, Inc. Assembly of high fidelity polynucleotides
CA2804604C (en) 2010-07-08 2023-10-03 United Biomedical, Inc. Designer peptide-based pcv2 vaccine
EP2637780B1 (en) 2010-11-12 2022-02-09 Gen9, Inc. Protein arrays and methods of using and making the same
CN103502448B (zh) 2010-11-12 2017-03-29 Gen9股份有限公司 核酸合成的方法和设备
EP2748318B1 (en) 2011-08-26 2015-11-04 Gen9, Inc. Compositions and methods for high fidelity assembly of nucleic acids
HUP1100470A2 (en) * 2011-08-30 2013-03-28 Mezoegazdasagi Biotechnologiai Kutatokoezpont Nanoparticle-based veterinary vaccine
US9150853B2 (en) 2012-03-21 2015-10-06 Gen9, Inc. Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
EP3543350B1 (en) 2012-04-24 2021-11-10 Gen9, Inc. Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
WO2014004393A1 (en) 2012-06-25 2014-01-03 Gen9, Inc. Methods for nucleic acid assembly and high throughput sequencing
WO2014153168A2 (en) * 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Porcine astrovirus sequences and uses thereof
JP6821429B2 (ja) 2013-09-25 2021-01-27 ゾエティス・サービシーズ・エルエルシー Ｐｃｖ２ｂ分岐ワクチン組成物及び使用方法
CN105658660A (zh) 2013-10-02 2016-06-08 勃林格殷格翰动物保健公司 Pcv2 orf2蛋白变体和由其组成的病毒样颗粒
CN103834670B (zh) * 2014-02-24 2016-01-06 福州大北农生物技术有限公司 优化的猪圆环病毒orf2截短基因
CN104593526B (zh) * 2015-02-05 2017-10-27 兰州生物制品研究所有限责任公司 一种用于猪圆环病毒检测的方法及引物组
US9944904B2 (en) 2015-05-14 2018-04-17 Merial Inc. Method for porcine circovirus production and PCV2 vaccines
EP3254692A1 (en) 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
TW202003027A (zh) 2018-03-26 2020-01-16 美商百靈佳殷格翰動物保健美國有限公司 製造免疫原組合物之方法
CN109021115B (zh) * 2018-08-06 2021-05-04 青岛明勤生物科技有限公司 一种猪圆环病毒三价亚单位疫苗
KR102211502B1 (ko) * 2019-08-12 2021-02-03 최영준 원적외선 원료를 활용한 피부접착용 패치
CN113322350B (zh) * 2021-05-06 2022-04-08 深圳海关动植物检验检疫技术中心 一种同时检测猪圆环病毒2型和猪圆环病毒3型病毒的试剂盒及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
JPS5873993U (ja) 1981-11-12 1983-05-19 三菱電機株式会社 ２気筒回転式圧縮機
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
GB8306426D0 (en) 1983-03-09 1983-04-13 Malcolm A D B Detecting polynucleotide sequence
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
ATE65092T1 (de) 1985-05-31 1991-07-15 Amoco Corp Verstaerkung von hybridisierungssignalen durch verwendung von komplementarischen dns-straengen.
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
SU1538305A1 (ru) 1987-07-21 1994-12-15 Всесоюзный государственный научно-контрольный институт ветеринарных препаратов Госагропрома СССР Ассоциированная вакцина против лептоспироза и парвовирусной инфекции свиней
ES2200016T3 (es) 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
ES2026827A6 (es) * 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
AU720640B2 (en) * 1995-06-07 2000-06-08 Leadd B.V. Neutralizing conformational epitopes of chicken anemia virus
FR2751224B1 (fr) * 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2769321B1 (fr) 1997-10-03 2001-10-26 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
CA2313806A1 (en) 1997-12-11 1999-06-17 University Of Saskatchewan Postweaning multisystemic wasting syndrome virus from pigs
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
WO2008151215A1 (en) * 2007-06-04 2008-12-11 Merial Limited Production of porcine circovirus proteins in plants

Also Published As

Publication number Publication date
JP3795751B2 (ja) 2006-07-12
DE69837934D1 (de) 2007-07-26
AU1552699A (en) 1999-06-28
KR20060088908A (ko) 2006-08-07
EP1037909B1 (en) 2007-06-13
US7144698B2 (en) 2006-12-05
DE69837934T2 (de) 2008-02-21
JP2006187289A (ja) 2006-07-20
ES2526760T3 (es) 2015-01-15
CA2313806A1 (en) 1999-06-17
HK1102829A1 (zh) 2007-12-07
KR100688008B1 (ko) 2007-02-27
CN1309708A (zh) 2001-08-22
KR20010033024A (ko) 2001-04-25
RU2000118777A (ru) 2002-07-10
EP2363488A1 (en) 2011-09-07
JP5848376B2 (ja) 2016-01-27
DE07008633T1 (de) 2008-12-18
WO1999029717A3 (en) 1999-10-07
PT2363488E (pt) 2015-01-13
BR9813485A (pt) 2000-10-17
US7741039B2 (en) 2010-06-22
JP5504056B2 (ja) 2014-05-28
AU764379B2 (en) 2003-08-14
US20030170616A1 (en) 2003-09-11
WO1999029717A2 (en) 1999-06-17
ES2289796T3 (es) 2008-02-01
EP1037909A2 (en) 2000-09-27
JP2013188211A (ja) 2013-09-26
ID28224A (id) 2001-05-10
CY1107720T1 (el) 2013-04-18
JP2010227115A (ja) 2010-10-14
NZ505008A (en) 2003-07-25
ATE364624T1 (de) 2007-07-15
KR20070101406A (ko) 2007-10-16
JP2014094016A (ja) 2014-05-22
EP2363488B1 (en) 2014-10-08
US20070099181A1 (en) 2007-05-03
JP2001525194A (ja) 2001-12-11
PT1037909E (pt) 2007-09-07
KR100879650B1 (ko) 2009-01-20
US20020106639A1 (en) 2002-08-08
DK1037909T3 (da) 2007-10-08

Similar Documents

Publication Publication Date Title
DK2363488T3 (da) Postweaning multisystemisk wasting syndrom-virus fra grise
US7803926B2 (en) Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
AU2005220241B2 (en) Reduction of porcine circovirus-2 viral load
US20060029617A1 (en) Porcine circovirus and Helicobacter combination vaccines and methods of use
EP1816200B1 (en) Postweaning multisystemic wasting syndrome virus for pigs
AU2003248395B2 (en) Porcine CircoViruses, vaccines and diagnostic reagents
AU2006202480B2 (en) Porcine circo viruses, vaccines and diagnostic reagents I
MXPA00005561A (es) Virus del sindrome de emaciacion multisistematica post-destete de cerdos